Rheumatism arthritis is a chronic, systemic, self-immunological disease that causes many pains, swelling and deformity to patients, which seriously affects the quality of life. In the treatment of rheumatism arthritis, biological agents have become a treatment that has received much attention in recent years, so is it working?
In terms of the mechanism of action, biological agents function mainly through the targeting of certain key elements in the system of rheumatological arthritis, such as cytogens or cell surface molecules. For example, tumour cause of death (TNF)-alpha inhibitor, which can accurately disrupt TNF-alpha, a cytogen that acts as a “push-up” during inflammation and joint destruction, thereby reducing the inflammation of the joints and the symptoms of pain and swelling. There are also biological agents that are targeted at other important immuno-regulating targets, such as white cellulose, which can also regulate disturbed immune systems and control progress.
Numerous clinical studies and practices have confirmed the effectiveness of biological agents. When many patients use biological agents, significant changes can be felt in a short period of time, where rigid and inflexible joints have become more flexible, and where severe pain and extended joint swelling have improved in the early morning. For patients with moderate and poor treatment of traditional rheumatological drugs, biological agents offer new hope that they can better control the situation, slow down the process of joint destruction and, to a certain extent, improve their self-care and quality of life.
However, biological agents are not always able to achieve the desired effect for all those affected by rheumatism arthritis. Some patients may be insensitive to the reactions to biological agents due to individual differences and, if used, the improvement of symptoms is limited. Moreover, there are constraints to the use of biological agents, such as relatively expensive prices, which may put some patients under economic pressure to remain in use for long periods of time; at the same time, the use of biological agents also requires rigorous monitoring of possible adverse effects, such as increased risk of infection, and doctors need to be careful to choose for patients after weighing the benefits and disadvantages.
In general, the biological agent of rheumatism arthritis is effective, opening new avenues for many patients to control their condition and improve their lives. However, the specific effects of the use vary from one person to another, requiring a comprehensive assessment of the patient ‘ s condition, state of health, financial capacity, etc., by a specialist doctor, who makes reasonable treatment decisions to ensure that, while performing his or her therapeutic role, he or she avoids the potential risks to the maximum benefit of the patient.
